svpn news
reuters.com ↗
Gilead Sciences said on Thursday it will acquire PepStar Therapeutics' oral inflammation drug program, including an experimental bowel disease treatment, for $1.275 billion in cash.
Log in or sign up to comment.
No comments yet.
← Back to stories
or login to continue
Already have an account? Log in
Log in or sign up to comment.